|
MIT works toward novel therapeutic device
October 23, 2007Applications include zapping cancer cells
CAMBRIDGE, Mass.-MIT and University of Rochester researchers report important advances toward a therapeutic device that has the potential to capture cells as they flow through the blood stream and treat them. Among other applications, such a device could zapp cancer cells spreading to other tissues, or signal stem cells to differentiate.
Their concept leverages cell rolling, a biological process that slows cells down as they flow through blood vessels. As the cells slow, they adhere to the vessel walls and roll, allowing them to sense signals from nearby tissues that may be calling them to work. Immune cells, for example, can be slowed and summoned to battle an infection.
"Through mimicking a process involved in many important physiological and pathological events, we envision a device that can be used to selectively provide signals to cells traveling through the bloodstream," said Jeffrey M. Karp of the Harvard-MIT Division of Health Sciences and Technology. "This technology has applications in cancer and stem cell therapies and could be used for diagnostics of a number of diseases."
The team, led by Karp, started with technology to induce cell rolling for research. With an implantable therapeutic device in mind, they improved that cell rolling technology to make it safe, more stable and longer lasting.
The improvements are described in the October 20 online issue of the journal Langmuir, published by the American Chemical Society.
In the body, P-selectin and other selectin proteins regulate cell rolling in blood vessels. When P-selectin is present on a vessel's inner wall, cells that are sensitive to it will stick to that patch and begin to roll across it.
To induce rolling in the laboratory, the original technology weakly adheres P-selectin to a glass surface and flows cells across it. This surface treatment remains stable for several hours then breaks down. "While this method is useful for experiments, it's not good for long-term stability," said Karp. An implantable device needs a coating that lasts weeks or even months so that patients won't need to come in frequently for replacements.
To improve the technology, the team experimented with several chemical methods to immobilize P-selectin on a glass surface. They identified a polyethelene glycol (PEG) coating that strongly bonded to P-selectin. This coating is also "non-fouling," meaning it does not react with or accumulate other proteins, so it is potentially safe for use in an implant.
P-selectin remains stable on this coating for longer than the original technology. In tests with microspheres coated with a molecule that interacts with P-selectin, these spheres slowed down significantly as they flowed over the surface coated with layers of PEG and P-selectin. The effect was stable past four weeks, the longest the devices have been tested.
To validate that this technology works with cells that are sensitive to P-selectin, the team flowed neutrophils (white blood cells) across the coated surface. They too slowed and rolled on surfaces treated with the new coating, and the effect again lasted for at least four weeks.
The next step is translating these results to animal studies and using the technology to slow and capture stem cells and cancer cells circulating in the blood stream.
Ultimately CellTraffix, Inc., a sponsor of this technology and its licensee, wants to apply the technique to a device that is either implanted into the blood stream or appended as a shunt. In addition to PEG and selectin molecules, the device would also include a therapeutic agent. Such an agent would interact only with certain cells for a specific purpose.
According to University of Rochester biomedical engineering professor Michael King, who developed the concept for adhesive capture and reprogramming of cells, the device could, for example, slow down metastatic, or spreading, cancer cells and kill them.
Massachusetts Institute of Technology
"Through mimicking a process involved in many important physiological and pathological events, we envision a device that can be used to selectively provide signals to cells traveling through the bloodstream," said Jeffrey M. Karp of the Harvard-MIT Division of Health Sciences and Technology. "This technology has applications in cancer and stem cell therapies and could be used for diagnostics of a number of diseases."
The team, led by Karp, started with technology to induce cell rolling for research. With an implantable therapeutic device in mind, they improved that cell rolling technology to make it safe, more stable and longer lasting.
The improvements are described in the October 20 online issue of the journal Langmuir, published by the American Chemical Society.
In the body, P-selectin and other selectin proteins regulate cell rolling in blood vessels. When P-selectin is present on a vessel's inner wall, cells that are sensitive to it will stick to that patch and begin to roll across it.
To induce rolling in the laboratory, the original technology weakly adheres P-selectin to a glass surface and flows cells across it. This surface treatment remains stable for several hours then breaks down. "While this method is useful for experiments, it's not good for long-term stability," said Karp. An implantable device needs a coating that lasts weeks or even months so that patients won't need to come in frequently for replacements.
To improve the technology, the team experimented with several chemical methods to immobilize P-selectin on a glass surface. They identified a polyethelene glycol (PEG) coating that strongly bonded to P-selectin. This coating is also "non-fouling," meaning it does not react with or accumulate other proteins, so it is potentially safe for use in an implant.
P-selectin remains stable on this coating for longer than the original technology. In tests with microspheres coated with a molecule that interacts with P-selectin, these spheres slowed down significantly as they flowed over the surface coated with layers of PEG and P-selectin. The effect was stable past four weeks, the longest the devices have been tested.
To validate that this technology works with cells that are sensitive to P-selectin, the team flowed neutrophils (white blood cells) across the coated surface. They too slowed and rolled on surfaces treated with the new coating, and the effect again lasted for at least four weeks.
The next step is translating these results to animal studies and using the technology to slow and capture stem cells and cancer cells circulating in the blood stream.
Ultimately CellTraffix, Inc., a sponsor of this technology and its licensee, wants to apply the technique to a device that is either implanted into the blood stream or appended as a shunt. In addition to PEG and selectin molecules, the device would also include a therapeutic agent. Such an agent would interact only with certain cells for a specific purpose.
According to University of Rochester biomedical engineering professor Michael King, who developed the concept for adhesive capture and reprogramming of cells, the device could, for example, slow down metastatic, or spreading, cancer cells and kill them.
Massachusetts Institute of Technology
Blood Vessel News and Current Blood Vessel Events RSSCertain anticancer agents could be harmful to patients with heart disease
A set of promising new anticancer agents could have unforeseen risks in individuals with heart disease, suggests research at Washington University School of Medicine in St. Louis.
Study in Circulation provides detail on how low blood flow promotes vascular disease
Researchers have found the first direct proof that a key protein drives the clogging of arteries in two ways, and that lowering levels of it opens them up, according to study results published in the June edition of the journal Circulation.
Failure to bridle inflammation spurs atherosclerosis
When a person develops a sore or a boil, it erupts, drawing to it immune system cells that fight the infection. Then it resolves and flattens into the skin, often leaving behind a mark or a scar.
Brief, intense exercise benefits the heart
Short bursts of high intensity sprints-known to benefit muscle and improve exercise performance-can improve the function and structure of blood vessels, in particular arteries that deliver blood to our muscles and heart, according to new research from McMaster University.
New method effective in detecting dangerous coronary plaque
A significant number of patients who suffer a heart attack never have any warning signs. For many of these individuals, the source of the problem is noncalcified plaque, a buildup of soft deposits embedded deep within the walls of the heart's arteries, undetectable by angiography or cardiac stress tests - and prone to rupture without warning.
Cocoa could be a healthy treat for diabetic patients
For people with diabetes, sipping a mug of steaming, flavorful cocoa may seem a guilty pleasure. But new research suggests that indulging a craving for cocoa can actually help blood vessels to function better and might soon be considered part of a healthy diet for the prevention of cardiovascular disease.
Natural compounds in cocoa tied to blood flow improvements for adults with type 2 diabetes
Scientists have found that consuming cocoa flavanols - naturally occurring compounds in cocoa - may offer a benefit to those affected by type-2 diabetes.
Virtual biopsy can tell whether colon polyp is benign without removal, Mayo researchers say
A probe so sensitive that it can tell whether or not a cell living within the human body is veering towards cancer development may revolutionize how future colonoscopies are done, say researchers from the Mayo Clinic in Jacksonville, Fla.
Drug fends off kidney cancer progression
New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments.
Study supports reason for concern in childhood and adolescent obesity
Study findings presented at the May 2008 Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting indicate that childhood and adolescent obesity negatively impacts vascular endothelial function, which relates to cardiac health.
More Blood Vessel News Articles
 | Introduction to Vascular Ultrasonography(Fifth Edition) by William Zwiebel, John Pellerito |
 | Operative Dictations in General and Vascular Surgery: Operative Dictations Made Simple |
 | General and Vascular Ultrasound: Case Review Series (Case Review) by William D. Middleton |
 | Vascular and Interventional Radiology: The Requisites by John A. Kaufman, Michael J. Lee |
 | Diagnostic Cerebral Angiography by Anne G Osborn |
 | Vascular Technology: An Illustrated Review by Claudia Rumwell, Michalene McPharlin |
 | Introduction to Vascular Scanning: A Guide for the Complete Beginner (Introductions to Vascular Technology)(3rd Edition) by Donald P. Ridgway |
 | Atlas of Vascular Anatomy: An Angiographic Approach by Renan Uflacker |
 | Vascular Medicine: A Companion to Braunwald's Heart Disease by Mark A. Creager, Victor J. Dzau, Joseph Loscalzo |
 | Vascular Surgery, 2-vol set by Robert B. Rutherford |
| © 2008 BrightSurf.com |